Finance Watch: Four IPOs In One Week
Public Company Edition: Veradermics grossed $294.8m, while Eikon brought in $381m, AgomAb grossed $200m and SpyGlass raised $150m, bringing this year’s US IPO count to five. Also, Adlai Nortye grossed $140m in a PIPE, while other companies cut jobs and programs.
Scrip - February 6, 2026

More Rivalry With Ionis In A Potentially ‘Transformational’ Year For Arrowhead
The company hopes to prove its RNAi platform is the most versatile and potent in cardiometabolic therapies in 2026 – and win one over on its long-standing rival, Ionis.
Scrip - February 6, 2026

Boston Scientific Says Penumbra Deal Could Lift Market Growth Profile As 10%+ Organic Target Holds
Boston Scientific also announced a new collaboration with Siemens Healthineers aimed at expanding its structural heart imaging capabilities. The companies plan to develop and commercialize a next-generation 4D intracardiac echocardiography catheter, ACUNAV.
Medtech Insight - February 6, 2026

Boston Scientific Sees EP Growth Exceeding Market Despite PFA Competition
Boston Scientific exits 2025 with roughly a 65% share of the PFA market, within a segment the company believes will grow about 15%.
Medtech Insight - February 6, 2026

Abbott Says Plans To Launch Dual Diabetes Sensor Unimpeded By Latest Warning Letter
A warning letter from the US FDA citing concerns of some Abbott continuous glucose monitors will not stop the company from launching a novel diabetes sensor later this year as planned.
Medtech Insight - February 6, 2026

Self?Care’s Future: Will AI Agents Decide What Health Consumers Buy?
AI advisers could eventually guide consumers toward health products based on personalized needs rather than traditional marketing, IQVIA Consumer Health suggests. But brands will still need to balance data?driven recommendations with the human appeal of in?store discovery and self?care experiences.
HBW Insight - February 6, 2026

Narasimhan Impressed With China’s Evolution Into Biopharma Pacesetter
The Novartis CEO believes the west has much to learn, especially in terms of clinical trial regulations and enrolment.
Scrip - February 6, 2026

More America First Fees: US FDA Proposes GDUFA Facility Fee Waiver For Domestic Construction
The FDA wants to waive facility fees for three years if a sponsor breaks ground on a US-based manufacturing plant, but industry is concerned the idea will force other sponsors to subsidize competition.
Generics Bulletin - February 6, 2026

Industry View: Good Year Shaping For Regulatory Progress In The UK – And EU
With EU MDR/IVDR review proposals out, UK MHRA progress on a premarket regulation and, up ahead, a prospective consultation on accepting the CE marking indefinitely, now is a good time to assess EU-UK regulatory positions for the benefit of UK industry, says ABHI director Steve Lee.
Medtech Insight - February 6, 2026

Pipeline Watch: Six Approvals And Four Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - February 6, 2026

Cereno Broadens CS014 Focus To PH-ILD To Sharpen Phase II Strategy
Cereno’s decision to include PH-ILD in CS014’s development strategy positions the asset for a Phase II study in a rare indication with limited treatment options, while maintaining its original relevance in IPF.
Scrip - February 6, 2026

Sandoz Enters Canadian Ophthalmology Market With Eylea Biosimilar
Sandoz’s aflibercept biosimilar Enzeevu launch in Canada comes just a few days after the firm signed a multiple asset deal, including an undisclosed ophthalmology product, with Alvotech, which recently gained immediate launch for its Eylea rival in the country.
Generics Bulletin - February 6, 2026

‘Access Is A Right, Not A Privilege’ – Medicines For Europe’s Saltofte Sets Out Priorities
After taking the reins as president of Medicines for Europe at the start of 2026, Zentiva CEO Steffen Saltofte sets out priorities for the group that include ensuring access to medicines, industry resilience and competitiveness, harmonized regulation, and sustainability for the off-patent sector.
Generics Bulletin - February 6, 2026

Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines.
Scrip - February 6, 2026

Positive PK Results Put Alvotech’s Vedolizumab Biosimilar On Path Toward Filings
Positive results from a randomized study in healthy volunteers mark a key milestone for Alvotech’s proposed Entyvio rivals AVT80 and AVT16.
Generics Bulletin - February 6, 2026

TrumpRx Launch Highlights MFN Drug Discounts, With Caveats
The Trump administration has launched TrumpRx, a website the White House says could help save Americans billions in pharmaceutical spending, although it does not itself sell or dispense drugs.
Scrip - February 6, 2026

German Switch Committee Rejects Controversial Painkiller Metamizole
Germany’s Expert Committee for Prescription (SVA) has unanimously rejected the proposed switch of the controversial painkiller metamizole from prescription to OTC status.
HBW Insight - February 6, 2026

Eisai Picks Up Henlius’s Serplulimab For Japan In $400m Deal
Henlius planning Japanese NDA by end of March 2027 for ES-SCLC and development in several other indications.
Scrip - February 6, 2026

US FDA Explains: ‘Artificial’ Color Added To Food Doesn’t Equal Not Native To The Product
Agency exercises enforcement discretion on requirement for products to be labeled as containing artificial colors or dyes when those aren’t native to foods or ingredients, including added colors made from natural sources.
HBW Insight - February 6, 2026